patpitchaya / Shutterstock.com
Teva has filed for a declaratory judgment that it did not infringe patents belonging to AstraZeneca and Amylin Pharmaceuticals that protect diabetes drug Byetta (exenatide).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, AstraZeneca, Amylin, Byetta, declaratory judgment